---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000640"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2023-01-11T23:59:59+00:00"
generated_at: "2026-06-20T16:39:49.652409+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ginkgo expects to meet 2022 total revenue guidance of $460-480M; cash ~$1.3B

## Summary
- Expects 55-60 new Cell Programs added in 2022, nearly doubling 2021 additions.
- Foundry revenue expected below $150-170M guidance; Biosecurity revenue exceeds $310M.
- Ended 2022 with approx. $1.3B cash; strong liquidity despite challenging macro.
- Opened Bioworks7 (6,600 sq ft BSL-2 lab) for mammalian cell engineering; launched Ginkgo Enzyme Services.
- Full audited Q4 and FY 2022 results due March 2023; 2023 outlook to be provided then.

## SEC filing metadata
- accession: 0000950170-23-000640
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2023-01-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000095017023000640/0000950170-23-000640-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000095017023000640/dna-20230111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000640
- JSON: https://secwatch.observer/filing/0000950170-23-000640.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000640.txt

## Key facts
- Earnings Releases
  Ginkgo Bioworks Holdings, Inc. reported the year ended December 31, 2022 results: revenue $460 – 480 million. Guidance reaffirmed.
  - Period: the year ended December 31, 2022
  - Revenue: $460 – 480 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: Key Performance Highlights • Ginkgo reiterated its expectations of 55-60 new Cell Programs added to the Foundry platform in 2022 • Ginkgo continues to expect Total revenue of $460 – 480 million in 2022 o Preliminary unaudited Foundry revenue is expected to be below the previously disclosed guidance of $150 – $170 million in 2022 due to a subset of targeted
  evidence_url: https://www.sec.gov/Archives/edgar/data/1830214/000095017023000640/0000950170-23-000640-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.